Bayer Bolsters Balance Sheet With EUR 2 Billion Hybrid Bond as Missouri Roundup Trial Tests a New Legal Theory

Bayer issued EUR 2 billion in hybrid bonds, lifting hybrid paper to EUR 6.55 billion, as BlueRock's lemiretprocel won US and EU orphan drug designations.

Bayer has returned to the debt market with a dual-tranche hybrid bond issue worth EUR 2 billion, a move that lifts the group's outstanding hybrid paper to EUR 6.55 billion and hands management fresh long-term firepower for corporate financing. The transaction, placed on 23 September, splits into two tranches carrying non-call periods of six and nine years respectively.

The extra liquidity arrives at a moment when the Leverkusen-based conglomerate is trying to keep two very different ledgers in balance: the research spending needed to refresh its pharmaceutical pipeline, and the debt reduction that market watchers want to see on the balance sheet. How Bayer manages that trade-off is now a central question for observers tracking the stock.

BlueRock Candidate Picks Up Orphan Status on Both Sides of the Atlantic

On the pipeline front, Bayer subsidiary BlueRock Therapeutics has secured orphan drug designation for its development candidate lemiretprocel (OpCT-001) from both the US Food and Drug Administration and the European Medicines Agency. The FDA's classification covers two indications — retinitis pigmentosa and cone-rod dystrophy — while the EMA granted the label for the broader spectrum of inherited retinal diseases.

The designation is designed to speed development of treatments for rare, serious conditions. For Bayer, it translates into procedural relief in the review process and market exclusivity should the therapy eventually win approval. Advancing specialized cell therapies sits squarely within the group's strategy of strengthening its product portfolio with innovative treatment approaches, and progress on new candidates is widely viewed as a key building block for future growth.

A Fresh Courtroom Battle in Missouri

Legal risk, however, has not gone away. According to a Reuters report, a trial over the herbicide Roundup has opened in a Missouri court, with plaintiffs alleging that Bayer failed to test the product adequately before selling it. The company rejects the accusations outright.

What sets this case apart from earlier litigation is its focus: rather than targeting allegedly missing warnings about cancer risks on the label, the claim zeroes in on pre-market product testing. That distinction matters for how the proceedings unfold.

Brussels Declines to Exempt Glyphosate From Routine Reviews

Regulatory politics around crop protection remains a live theme in Europe as well. EU member states rejected a proposal that would have exempted glyphosate from regular approval procedures in the future. The vote relates to a planned overhaul of the general authorization rules for plant protection products and, as Bayer made clear, carries no immediate consequence for glyphosate's existing approval.

Maintenance Work in Bergkamen

Closer to home, the company flagged an operational measure at one of its German sites. Starting 5 October 2026, Bayer will take the existing primary clarifier at the Bergkamen wastewater treatment plant out of service. The company said temporary odors may occur during the conversion work, adding that they pose no health risk to the surrounding area.

Where the Shares Stand

The stock has been feeling the weight of these overlapping pressures. Bayer closed Friday at EUR 45.02, a drop of 10% from the prior week, though it still trades above its 200-day moving average of EUR 43.09. In today's session the paper changed hands at EUR 44.89, a modest daily decline of 0.9%, as many market participants hold back ahead of fresh signals on earnings power.

Those signals are not far off. Media reports point to Bayer publishing third-quarter results on 3 November. Analysts continue to see upside in the shares despite the cautious mood, with the coming business figures and the group's operational discipline — alongside the regulatory strides in the pipeline — likely to shape the next leg of the story for the DAX constituent.